Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

被引:177
作者
Birkinshaw, Richard W. [1 ,2 ]
Gong, Jia-nan [1 ,2 ]
Luo, Cindy S. [1 ,2 ]
Lio, Daisy [1 ,2 ]
White, Christine A. [1 ,2 ]
Anderson, Mary Ann [1 ,2 ,3 ,4 ]
Blombery, Piers [3 ,4 ,5 ,6 ]
Lessene, Guillaume [1 ,2 ,7 ]
Majewski, Ian J. [1 ,2 ]
Thijssen, Rachel [1 ,2 ]
Roberts, Andrew W. [1 ,2 ,3 ,4 ,8 ,9 ]
Huang, David C. S. [1 ,2 ]
Colman, Peter M. [1 ,2 ]
Czabotar, Peter E. [1 ,2 ]
机构
[1] Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3052, Australia
[3] Peter MacCallum Canc Ctr, Clin Haematol, Melbourne, Vic 3000, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia
[5] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic 3000, Australia
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3000, Australia
[7] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic 3010, Australia
[8] Univ Melbourne, Ctr Canc Res, Melbourne, Vic 3000, Australia
[9] Victorian Comprehens Canc Ctr, Melbourne, Vic 3000, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
FAMILY PROTEINS; CRYSTAL-STRUCTURE; INHIBITOR; POTENT; ANTAGONISTS; APOPTOSIS; ABT-199; MCL-1;
D O I
10.1038/s41467-019-10363-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing therapy. To understand the molecular basis of this acquired resistance we describe the crystal structures of venetoclax bound to both BCL-2 and the G101V mutant. The pose of venetoclax in its binding site on BCL-2 reveals small but unexpected differences as compared to published structures of complexes with venetoclax analogues. The G101V mutant complex structure and mutant binding assays reveal that resistance is acquired by a knock-on effect of V101 on an adjacent residue, E152, with venetoclax binding restored by a E152A mutation. This provides a framework for considering analogues of venetoclax that might be effective in combating this mutation.
引用
收藏
页数:10
相关论文
共 43 条
[1]   PHENIX: a comprehensive Python']Python-based system for macromolecular structure solution [J].
Adams, Paul D. ;
Afonine, Pavel V. ;
Bunkoczi, Gabor ;
Chen, Vincent B. ;
Davis, Ian W. ;
Echols, Nathaniel ;
Headd, Jeffrey J. ;
Hung, Li-Wei ;
Kapral, Gary J. ;
Grosse-Kunstleve, Ralf W. ;
McCoy, Airlie J. ;
Moriarty, Nigel W. ;
Oeffner, Robert ;
Read, Randy J. ;
Richardson, David C. ;
Richardson, Jane S. ;
Terwilliger, Thomas C. ;
Zwart, Peter H. .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 :213-221
[2]   MX2: a high-flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian Synchrotron [J].
Aragao, David ;
Aishima, Jun ;
Cherukuvada, Hima ;
Clarken, Robert ;
Clift, Mark ;
Cowieson, Nathan Philip ;
Ericsson, Daniel Jesper ;
Gee, Christine L. ;
Macedo, Sofia ;
Mudie, Nathan ;
Panjikar, Santosh ;
Price, Jason Roy ;
Riboldi-Tunnicliffe, Alan ;
Rostan, Robert ;
Williamson, Rachel ;
Caradoc-Davies, Thomas Tudor .
JOURNAL OF SYNCHROTRON RADIATION, 2018, 25 :885-891
[3]  
Berger S, 2016, ELIFE, V5, DOI [10.7554/eLife.20352, 10.7554/elife.20352]
[4]   Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia [J].
Blombery, Piers ;
Anderson, Mary Ann ;
Gong, Jia-nan ;
Thijssen, Rachel ;
Birkinshaw, Richard W. ;
Thompson, Ella R. ;
Teh, Charis E. ;
Nguyen, Tamia ;
Xu, Zhen ;
Flensburg, Christoffer ;
Lew, Thomas E. ;
Majewski, Ian J. ;
Gray, Daniel H. D. ;
Westerman, David A. ;
Tam, Constantine S. ;
Seymour, John F. ;
Czabotar, Peter E. ;
Huang, David C. S. ;
Roberts, Andrew W. .
CANCER DISCOVERY, 2019, 9 (03) :342-353
[5]   Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL [J].
Bruncko, Milan ;
Oost, Thorsten K. ;
Belli, Barbara A. ;
Ding, Hong ;
Joseph, Mary K. ;
Kunzer, Aaron ;
Martineau, Darlene ;
McClellan, William J. ;
Mitten, Michael ;
ng, Shi-Chu Ng ;
Nimmer, Paul M. ;
Oltersdorf, Tilman ;
Park, Cheol-Min ;
Petros, Andrew M. ;
Shoemaker, Alexander R. ;
Song, Xiaohong ;
Wang, Xilu ;
Wendt, Michael D. ;
Zhang, Haichao ;
Fesik, Stephen W. ;
Rosenberg, Saul H. ;
Elmore, Steven W. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) :641-662
[6]  
Casara Patrick, 2018, Oncotarget, V9, P20075, DOI 10.18632/oncotarget.24744
[7]   α/β-Peptide Foldamers Targeting Intracellular Protein-Protein Interactions with Activity in Living Cells [J].
Checco, James W. ;
Lee, Erinna F. ;
Evangelista, Marco ;
Sleebs, Nerida J. ;
Rogers, Kelly ;
Pettikiriarachchi, Anne ;
Kershaw, Nadia J. ;
Eddinger, Geoffrey A. ;
Belair, David G. ;
Wilson, Julia L. ;
Eller, Chelcie H. ;
Raines, Ronald T. ;
Murphy, William L. ;
Smith, Brian J. ;
Gellman, Samuel H. ;
Fairlie, W. Douglas .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (35) :11365-11375
[8]   MolProbity: all-atom structure validation for macromolecular crystallography [J].
Chen, Vincent B. ;
Arendall, W. Bryan, III ;
Headd, Jeffrey J. ;
Keedy, Daniel A. ;
Immormino, Robert M. ;
Kapral, Gary J. ;
Murray, Laura W. ;
Richardson, Jane S. ;
Richardson, David C. .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 :12-21
[9]   Targeting BCL-2-like Proteins to Kill Cancer Cells [J].
Cory, Suzanne ;
Roberts, Andrew W. ;
Colman, Peter M. ;
Adams, Jerry M. .
TRENDS IN CANCER, 2016, 2 (08) :443-460
[10]   Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy [J].
Czabotar, Peter E. ;
Lessene, Guillaume ;
Strasser, Andreas ;
Adams, Jerry M. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2014, 15 (01) :49-63